Healthcare
Telix Pharmaceuticals Limited(TLX)
Live Price
Offline$9.56
+1.16% today
1Y Change
-44.37%
Window
Jun 20, 2025 → Jun 15, 2026
- Market Cap
- $5.28B
- Revenue Growth
- +53.9%
- EPS Growth
- -121.1%
- Dividend Yield
- 0.0%
Coverage: 247 bars · Jun 20, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Telix Pharmaceuticals Limited (TLX) is a Healthcare stock with a market cap of $5.28B and listed on NASDAQ. The stock last traded around $9.56 and down 44.4% across the available one-year price window (Jun 20, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +53.9%, EPS growth of -121.1%, a dividend yield of 0.0%. What stands out right now is revenue +53.9%, EPS -121.1%, free cash flow -388.4% with operating margin 2.1% and ROIC 1.8%. Valuation sits in the middle of the pack at price/sales 4.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TLX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+53.9% vs +7.6% peer median
Operating Margin
Below sector median
+2.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at +53.9% and EPS is at -121.1%, with operating margin around 2.1%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TLX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TLX Max Drawdown
-62.62%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TLX and SPY.
Company Overview
Telix Pharmaceuticals Limited
NASDAQ Global Select
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
- Leadership
- Christian Behrenbruch
- IPO Date
- Nov 14, 2024
- Employees
- 1.1k
- Street Address
- 55 Flemington Road
- Mailing
- North Melbourne, VIC, 3051
- Region
- North Melbourne, VIC, AU
- Reporting Currency
- USD
- Investor Line
- 61 3 9093 3855
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- 157.9
- Price/Sales
- 4.3
- Price/Book
- 8.5
Growth
- Revenue
- +53.9%
- EPS
- -121.1%
- Free Cash Flow
- -388.4%
Profitability
- Gross Margin
- 50.8%
- Operating Margin
- 2.1%
- Net Margin
- -0.9%
- ROE
- -2.1%
- ROIC
- 1.8%
Balance Sheet
- Debt/Equity
- 1.26
- Current Ratio
- 1.43
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.